Xenon Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Xenon Pharmaceuticals de 23.7% y 62.7% por año respectivamente. Se prevé que el BPA crezca en un 27.2% al año. Se espera que la rentabilidad financiera sea de -48% en 3 años.

Información clave

22.1%

Tasa de crecimiento de los beneficios

25.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	67.7%
Rentabilidad financiera futura	-44.1%
Cobertura de analistas	Good
Última actualización	13 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Apr 16

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Mar 12

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'

Feb 08

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Oct 21

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Jun 22

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Feb 15

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Oct 27

Xenon started at outperform at Raymond James on experimental epilepsy drug

Oct 19

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Sep 22

Putting Xenon Pharmaceuticals Back In The Spotlight

Sep 06

Xenon initiated with Buy at BofA citing potential of anti-seizure drug

Aug 29

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Jun 13

Sizing Up Xenon Pharmaceuticals

Dec 13

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Nov 12

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Aug 05

Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%

May 13

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Apr 14

Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?

Mar 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:XENE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	57	-295	-247	N/A	14
12/31/2025	9	-262	-171	N/A	17
12/31/2024	2	-221	-223	N/A	17
3/31/2024	N/A	-189	N/A	N/A	N/A
12/31/2023	N/A	-182	-151	-145	N/A
9/30/2023	N/A	-175	-150	-143	N/A
6/30/2023	0	-164	-137	-131	N/A
3/31/2023	1	-147	-119	-114	N/A
12/31/2022	9	-126	-101	-98	N/A
9/30/2022	13	-113	-88	-86	N/A
6/30/2022	21	-91	-73	-71	N/A
3/31/2022	23	-83	-69	-67	N/A
12/31/2021	18	-81	-72	-70	N/A
9/30/2021	20	-66	-64	-62	N/A
6/30/2021	18	-59	-61	-58	N/A
3/31/2021	29	-37	-58	-56	N/A
12/31/2020	32	-29	-51	-48	N/A
9/30/2020	30	-28	-18	-15	N/A
6/30/2020	27	-28	-13	-11	N/A
3/31/2020	14	-38	-11	-9	N/A
12/31/2019	7	-42	-6	-5	N/A
9/30/2019	4	-39	-33	-32	N/A
6/30/2019	N/A	-44	-39	-38	N/A
3/31/2019	N/A	-42	-36	-35	N/A
12/31/2018	N/A	-34	-35	-35	N/A
9/30/2018	0	-34	-35	-34	N/A
6/30/2018	0	-27	-30	-29	N/A
3/31/2018	0	-27	-31	-30	N/A
12/31/2017	0	-31	N/A	-29	N/A
9/30/2017	1	-29	N/A	-27	N/A
6/30/2017	1	-29	N/A	-22	N/A
3/31/2017	1	-27	N/A	-21	N/A
12/31/2016	2	-23	N/A	-20	N/A
9/30/2016	5	-21	N/A	-20	N/A
6/30/2016	9	-17	N/A	-21	N/A
3/31/2016	12	-10	N/A	-17	N/A
12/31/2015	16	-16	N/A	-18	N/A
9/30/2015	17	-2	N/A	-16	N/A
6/30/2015	26	5	N/A	-5	N/A
3/31/2015	27	4	N/A	-4	N/A
12/31/2014	28	13	N/A	0	N/A
9/30/2014	29	6	N/A	1	N/A
6/30/2014	27	4	N/A	-1	N/A
3/31/2014	27	4	N/A	-1	N/A
12/31/2013	27	4	N/A	-3	N/A
9/30/2013	25	0	N/A	19	N/A
6/30/2013	17	-3	N/A	34	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que XENE siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que XENE siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que XENE siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (62.7% al año) de XENE crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (62.7% al año) de XENE crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: XENE se prevé que no sea rentable en 3 años.

Xenon Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 22%

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 19%

Consensus forecasts updated

Consensus forecasts updated

Price target increased to US$48.82

Recent updates

Xenon Pharmaceuticals Inc. to Report Q1, 2024 Results on May 09, 2024

Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Independent Director recently sold US$602k worth of stock

Xenon Pharmaceuticals Inc., Annual General Meeting, Jun 04, 2024

Xenon Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'

Consensus revenue estimates decrease by 22%

Independent Director recently sold US$312k worth of stock

Independent Director notifies of intention to sell stock

Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $300.000013 million.

Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $300.000013 million.

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder (Mdd)

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder (Mdd)

Consensus revenue estimates decrease by 23%

Xenon Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Xenon Pharmaceuticals Announces Publication of Results from Xen1101 Phase 2B "X-Tole" Clinical Trial in Peer-Reviewed Journal Article in Jama Neurology

Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

High number of new directors

Lead Independent Director recently sold US$968k worth of stock

Consensus revenue estimates fall by 19%

First half 2023 earnings released: US$1.38 loss per share (vs US$0.87 loss in 1H 2022)

Xenon Pharmaceuticals Inc. Announces Board Appointments

Xenon Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Chairman of the Board recently sold US$4.2m worth of stock

President notifies of intention to sell stock

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.37 loss in 1Q 2022)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Xenon Pharmaceuticals Inc. Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Independent Director recently sold US$71k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xenon Pharmaceuticals Inc. Announces Appointment of Andrea Difabio as Chief Legal Officer and Corporate Secretary

Xenon Pharmaceuticals Inc. Announces Launch of XEN1101 Phase 3 Program with Initiation of X TOLE2 Clinical Trial in Patients with Focal Onset Seizures

Xenon Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Now 20% undervalued

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Xenon started at outperform at Raymond James on experimental epilepsy drug

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Putting Xenon Pharmaceuticals Back In The Spotlight

Insider exercised options and sold US$2.5m worth of stock

Xenon initiated with Buy at BofA citing potential of anti-seizure drug

Chairman of the Board recently sold US$6.8m worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$48.82

Xenon Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Xenon Pharmaceuticals Inc. Announces Michael Hayden Will Not Stand for Re-Election as Member of Board

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as Treatment for Major Depressive Disorder

Executive Chairman recently sold US$734k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Xenon Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 01, 2022

Xenon Pharmaceuticals Inc. announced that it expects to receive $8.249999 million in funding from Neurocrine Biosciences, Inc.

Sizing Up Xenon Pharmaceuticals

Chief Commercial Officer recently bought US$98k worth of stock

Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society

Executive Chairman recently sold US$550k worth of stock

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.25 loss in 3Q 2020)

Price target increased to US$41.00